Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 04, 2026 | June 08, 2026 |
| Bausch Health Companies Inc.BHC · Entity 4363 | President, Ortho-Dermatologics | December 04, 2020 | December 08, 2020 |
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2024 | June 21, 2024 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | July 05, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,105 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 45,105 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03 | Direct | 42,350 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,987 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5: The shares underlying these restricted stock units vested on June 5, 2026.
Bausch Health Companies Inc.
Report date December 04, 2020 · Filed December 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 235,035 |
Ending reported balance
After 2020-12-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-04 · Exercise / conversion · Acquired 114,055 · Balance 349,090 Row 2 · 2020-12-04 · Sale · Disposed 114,055 · Balance 235,035 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.82 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. |
| Non-qualified Stock Options (right To Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $14.38 · Expires 2027-03-01 | Direct | 0 |
Reported balance
After 2020-12-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-04 · Exercise / conversion · Disposed 114,055 · Balance 0 F2: The options vest in equal installments on each of the first three anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.82 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote.
F2: The options vest in equal installments on each of the first three anniversaries of the date of grant.
Clearside Biomedical, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19 | Direct | 45,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,538 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 2,538 · Balance 2,538 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Disposed 2,538 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
STRATA Skin Sciences, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 109,724 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 36,408 · Balance 109,724 F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 21,658 | $19.63 | $425,196.35 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 4 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,035 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.66 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 21,658 | $14.38 | $311,442.04 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionNon-qualified Stock Options (right To Purchase) · Derivative | 1,483 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · derivative · entry 7 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,376 Underlying: Common Shares, No Par Value · 1,483 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| November 23, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 1,483 | $19.63 | $29,115.44 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 3 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,035 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.64 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 30, 2020 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 1,483 | $14.38 | $21,325.54 |
DisclosureSEC source: 0001127602-20-030120 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:34 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 5,667 | $16.17 | $91,635.39 |
DisclosureSEC source: 0001127602-20-024896 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,035 F1 · kind: The sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 23:53 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 5,586 | $1.78 | $9,943.08 |
DisclosureSEC source: 0001209191-20-047348 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,586 Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 23:12 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 4,567 | $17.48 | $79,831.16 |
DisclosureSEC source: 0001127602-20-023930 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,702 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:36 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037947 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 18, 2021. Read SEC document |
| June 06, 2020 Filed Jun 8, 2020 21:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035032 · doc4.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F4 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document |
| June 06, 2020 Filed Jun 8, 2020 21:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035032 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantOption Grant (right to buy) · Derivative | 16,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-20-035032 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 8,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016078 · doc4.xml · derivative · entry 3 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 8,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016078 · doc4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:24 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016078 · doc4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:26 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 2,264 | $24.44 | $55,332.16 |
DisclosureSEC source: 0001127602-20-009139 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,269 F1 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:28 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 56,858 | $0.00 Strike: $24.77 | $0.00 |
DisclosureSEC source: 0001127602-20-008444 · form4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,858 Underlying: Common Shares, No Par Value · 56,858 shares Expires 2030-02-26 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:28 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 13,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008444 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,533 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 01:54 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 56,532 | $26.46 | $1,495,836.72 |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 3 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,027 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 20,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · derivative · entry 4 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on January 4, 2017 with the maximum potential award amount of 41,002 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 105,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,559 Read SEC document |
| February 19, 2020 Filed Feb 25, 2020 01:54 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Stock, No Par Value | 20,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007430 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 2, 2017. F2 · shares: On January 2, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 21:18 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 14,559 | $29.92 | $435,605.28 |
DisclosureSEC source: 0001127602-20-001277 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,865 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 20:17 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 30,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-027064 · form4.xml · nonDerivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,424 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 20:17 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Stock, No Par Value | 30,703 | $21.18 | $650,142.17 |
DisclosureSEC source: 0001127602-19-027064 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,721 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.13 to $21.18 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range provided in this footnote. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:26 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-19-038770 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next meeting of stockholders or June 20, 2020. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035840 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:11 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 44,290 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009252 · form4.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,290 Underlying: Common Shares, No Par Value · 44,290 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:11 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 15,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009252 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,018 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:22 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 13,311 | $18.47 | $245,854.17 |
DisclosureSEC source: 0001127602-19-001498 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,797 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:19 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-038983 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:01 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $18.35 | $0.00 |
DisclosureSEC source: 0001209191-18-036650 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 20:58 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 14,730 | $20.78 | $306,089.40 |
DisclosureSEC source: 0001127602-18-001241 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · EVP, COMPANY GROUP CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,108 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:05 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 2,632 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001209191-17-043402 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632 Underlying: Common Stock · 2,632 shares Expires 2027-06-29 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 30, 2018. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:38 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 8,618 | $0.00 Strike: $8.81 | $0.00 |
DisclosureSEC source: 0001209191-17-041676 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,618 Underlying: Common Stock · 8,618 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 23:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.58 | $0.00 |
DisclosureSEC source: 0001209191-17-040673 · doc4.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 22:51 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 150,859 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001681871-17-000008 · primary_doc.xml · derivative · entry 1 Humphries William D. · CIK 0001674278 · EVP, COMPANY GROUP CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,859 Underlying: Common Shares, no par value · 150,859 shares Expires 2027-03-01 F1 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 01:41 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 41,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001674278-17-000004 · primary_doc.xml · derivative · entry 2 Humphries William D. · CIK 0001674278 · EVP, Company Group Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,002 Underlying: Common Stock · 41,002 shares Expires 2020-01-02 F2 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 20,501 and the maximum number that can be distributed is 41,002. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured on January 2, 2020 (the "Measurement Date"). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F2 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 20,501 and the maximum number that can be distributed is 41,002. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured on January 2, 2020 (the "Measurement Date"). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 01:41 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 129,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001674278-17-000004 · primary_doc.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · EVP, Company Group Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,838 F1 · shares: Represents the award of Restricted Share Units ("RSUs") which will vest one-third on each of the three anniversaries following the date of grant, subject to the reporting person's continued service subject to continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.